GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Investments And Advances

Chimeric Therapeutics (ASX:CHM) Investments And Advances : A$0.04 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Investments And Advances?

Chimeric Therapeutics's Investments And Advances for the quarter that ended in Dec. 2023 was A$0.04 Mil.

Chimeric Therapeutics's quarterly Investments And Advances stayed the same from Dec. 2022 (A$0.04 Mil) to Jun. 2023 (A$0.04 Mil) and stayed the same from Jun. 2023 (A$0.04 Mil) to Dec. 2023 (A$0.04 Mil).

Chimeric Therapeutics's annual Investments And Advances increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$0.04 Mil) but then stayed the same from Jun. 2022 (A$0.04 Mil) to Jun. 2023 (A$0.04 Mil).


Chimeric Therapeutics Investments And Advances Historical Data

The historical data trend for Chimeric Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Investments And Advances Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Investments And Advances
- 0.04 0.04

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial - 0.04 0.04 0.04 0.04

Chimeric Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines